Activist Investor Starboard Criticizes Pfizer for R&D Failures and Acquisition Costs
Tuesday, 22 October 2024, 10:55
Starboard's Critique of Pfizer
Starboard Value has expressed significant concern regarding Pfizer's (PFE) management decisions, particularly in the realm of research and development (R&D). The firm argues that underperforming R&D initiatives and overpaying for acquisitions have contributed to a steep decline in stock value.
Major Findings
- 50% stock decline since the pandemic.
- Missed growth targets raise eyebrows.
- Calls for strategic overhaul in management.
Investors are now questioning whether Pfizer can navigate this criticism and lead the healthcare marketplace effectively.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.